Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Protalix Biotherapeutics Inc PLX

Healthcare Biotechnology
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the... see more

Recent & Breaking News (NYSEAM:PLX)

Protalix BioTherapeutics Announces Pricing of $60 Million Offering of Convertible Notes

Globe Newswire September 12, 2013

Protalix BioTherapeutics Announces Proposed $60 Million Offering of Convertible Notes

Globe Newswire September 11, 2013

Protalix BioTherapeutics Discloses Three New Compounds in Development

Globe Newswire June 20, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on DVAX, MNOV, NKTR and PLX

Accesswire June 20, 2013

Protalix BioTherapeutics and Brazil's Ministry of Health Enter Into Supply and Technology Transfer Agreement for UPLYSO(TM) (alfataliglicerase) in Brazil

Globe Newswire June 19, 2013

Protalix BioTherapeutics to Host Analyst Event in New York City

Globe Newswire June 12, 2013

Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences

Globe Newswire May 29, 2013

Protalix BioTherapeutics to Present at the Oppenheimer 14th Annual Israeli Conference

Globe Newswire May 8, 2013

Free Research Reports on GWAY, HNT, MDSO and PLX Issued by the Paragon Report

Marketwired April 30, 2013

UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease

Globe Newswire April 29, 2013

U.S. Food and Drug Administration Approved 30% More Drugs in 2012 Than the Year Previous

Marketwired March 19, 2013

UPLYSO(TM) (alfataliglicerase) Approved in Brazil by ANVISA for the Treatment of Gaucher Disease

Troy Schwensen March 18, 2013

Protalix BioTherapeutics Receives Approval to Initiate Phase I Study in Gaucher Patients With PRX-112, an Orally-Administered Candidate for the Treatment of Gaucher Disease

Troy Schwensen March 7, 2013

Protalix Announces New Clinical Data on ELELYSO(TM) to be Presented at the WORLD Symposium 2013

Troy Schwensen February 13, 2013

Mergers and Acquisitions on the Rise in 2013 as Big Pharma Companies Hold Record Amounts of Cash on Hand

Marketwired February 7, 2013

Free Research Reports on IMUC, NBIX, OPXA and PLX Issued by the Bedford Report

Marketwired February 6, 2013

Squawk Box Stocks Reports On: Opexa Therapeutics, Inc. (NASDAQ: OPXA), ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC), Protalix BioTherapeutics, Inc. (NYSE MKT: PLX), Titan Pharmaceuticals Inc. (OTCQB: TTNP).

Marketwired February 6, 2013

Protalix BioTherapeutics to Present at the 15th Annual BIO CEO & Investor Conference

Troy Schwensen February 5, 2013

Protalix BioTherapeutics Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Network Symposium

Troy Schwensen January 31, 2013